
Miloš Grujić//LinkedIn
Apr 19, 2025, 01:19
Milos Grujic: Patient-Reported Outcomes with Talazoparib plus Enzalutamide
Milos Grujic, Head of Department of the subspecialist cabinets at the Center for Radiation Oncology at the University Clinical Center Kragujevac, shared a post on X:
“In TALAPRO-2, Talazoparib plus Enzalutamide significantly delayed QoL deterioration in mCRPC patients with HRR alterations.
Median: 27.1 vs 19.3 months
HR: 0.69 | p=0.032
Better QoL, longer control.
Lancet Oncology 2025.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 19, 2025, 13:43
Apr 19, 2025, 13:05